Advanced New Therapeutics And Diagnostics In Retinal Diseases And Glaucoma
Funder
National Health and Medical Research Council
Funding Amount
$3,550,944.00
Summary
This program proposal targets the most common blinding diseases in clinical ophthalmology. The applicant team includes research and clinical ophthalmologists and basic scientists. The team have an internationally established reputation in bringing basic science discoveries to the point where they can impact directly on clinical diagnosis and therapy. The proposed research includes new treatment therapies for diabetic retinopathy, age related macular degeneration, and retinal vascular diseases. A ....This program proposal targets the most common blinding diseases in clinical ophthalmology. The applicant team includes research and clinical ophthalmologists and basic scientists. The team have an internationally established reputation in bringing basic science discoveries to the point where they can impact directly on clinical diagnosis and therapy. The proposed research includes new treatment therapies for diabetic retinopathy, age related macular degeneration, and retinal vascular diseases. A new diagnostic technique for glaucoma and new instrumentation for detecting areas of poor blood flow and oxygen supply in the eye are also to be developed. Past successes in our current program grant make us confident that we can produce clinically useful outcomes from this new proposal.Read moreRead less
A Program Of Research Addressing The Transition From Health To Advanced Cardiovascular Disease.
Funder
National Health and Medical Research Council
Funding Amount
$13,017,057.00
Summary
Cardiovascular disease (CVD) is the major cause of death and disability in Australia and worldwide. This burden will increase without new knowledge. We will address knowledge gaps that delay more effective prevention and control. Our team has a strong track record of influencing clinical practice of CVD prevention, treatment and technology transfer. For many, the first indication of a heart problem is sudden heart attack or death. By understanding mechanisms we aim to develop new tests and treat ....Cardiovascular disease (CVD) is the major cause of death and disability in Australia and worldwide. This burden will increase without new knowledge. We will address knowledge gaps that delay more effective prevention and control. Our team has a strong track record of influencing clinical practice of CVD prevention, treatment and technology transfer. For many, the first indication of a heart problem is sudden heart attack or death. By understanding mechanisms we aim to develop new tests and treatments that prevent heart attack, heart failure and other serious consequences of atherosclerosis.Read moreRead less
A major obstacle to the development of safer and more effective pain treatments is the poorly defined nature of the different pathways involved in chronic pain. The applicant team bring together a unique set of research expertise in using neurotoxins to define, at the molecular level, how the nervous system functions. The applicants also share a common interest in understanding and improving treatments for pain, especially chronic pain which continues to remain poorly managed Through a focus on ....A major obstacle to the development of safer and more effective pain treatments is the poorly defined nature of the different pathways involved in chronic pain. The applicant team bring together a unique set of research expertise in using neurotoxins to define, at the molecular level, how the nervous system functions. The applicants also share a common interest in understanding and improving treatments for pain, especially chronic pain which continues to remain poorly managed Through a focus on pain research, the Program will significantly enhance the scope of existing multidisciplinary collaborations between the Cis Lewis Alewood, Adams and Christie, which have already made a considerable impact in the fields of pharmacology and neuroscience. The CIs also have considerable experience in the development of pain therapeutics, having discovered two conopeptides now under commercial development with AMRAD (AM336) and Xenome Ltd (Xen2174). This Program will discover and use highly selective conopeptides such as these to dissect the pharmacology of peripheral pain pathways and their projections into the central nervous system, and to identify and characterise new targets amenable to drug intervention. The long-term goal of the Program is to discover new targets in pain pathways and develop conopeptides that act on these targets in animal models of chronic pain. These molecules will be optimised within the Program to the point where they can be considered for pre-clinical development in collaboration with commercial partners.Read moreRead less